VivoSim Labs, Inc. Cash Flow Conversion Efficiency
VivoSim Labs, Inc. cash flow conversion efficiency. Based on the latest financial reports, VivoSim Labs, Inc. (VIVS) has a cash flow conversion efficiency ratio of 1.370x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.21 Million) by net assets ($-2.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of VivoSim Labs, Inc. (2011–2026)
Cash flow conversion efficiency of VivoSim Labs, Inc. from 2011 to 2026. This chart illustrates how VivoSim Labs, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View VivoSim Labs, Inc. share price for real-time trading data and today's change.
VivoSim Labs, Inc. Cash Flow Conversion Ratio Explained
VivoSim Labs, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
VivoSim Labs, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VivoSim Labs, Inc. ranked by their cash flow conversion efficiency. Also see VivoSim Labs, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aker Carbon Capture ASA
OL:ACC
|
-0.772x |
|
HCW Biologics Inc
NASDAQ:HCWB
|
-0.534x |
|
ELEMENT NUTR.SCIENCES
F:93X
|
0.014x |
|
Chakana Copper Corp
V:PERU
|
-0.248x |
|
Unicorn AIM VCT plc
LSE:UAV
|
-0.006x |
|
HYDRIX Ltd
AU:HYD
|
0.279x |
|
Providence Gold Mines
V:PHD
|
0.360x |
|
Foresight Enterprise VCT PLC
LSE:FTF
|
-0.001x |
Annual Cash Flow Conversion Efficiency for VivoSim Labs, Inc. (2011–2026)
The table below shows the annual cash flow conversion efficiency of VivoSim Labs, Inc. from 2011 to 2026. Review financial agility of VivoSim Labs, Inc. to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $-1.10 Million | $-10.83 Million | 9.852x | +1192.53% |
| 2025-03-31 | $10.49 Million | $-9.46 Million | -0.902x | +77.84% |
| 2024-03-31 | $3.60 Million | $-14.65 Million | -4.069x | -402.71% |
| 2023-03-31 | $15.33 Million | $-12.41 Million | -0.809x | -189.28% |
| 2022-03-31 | $30.21 Million | $-8.45 Million | -0.280x | +17.68% |
| 2021-03-31 | $39.20 Million | $-13.32 Million | -0.340x | +39.17% |
| 2020-03-31 | $26.63 Million | $-14.88 Million | -0.559x | +0.45% |
| 2019-03-31 | $36.30 Million | $-20.38 Million | -0.561x | +13.27% |
| 2018-03-31 | $44.59 Million | $-28.86 Million | -0.647x | -38.30% |
| 2017-03-31 | $62.36 Million | $-29.18 Million | -0.468x | +0.91% |
| 2016-03-31 | $62.18 Million | $-29.37 Million | -0.472x | -17.34% |
| 2015-03-31 | $48.70 Million | $-19.60 Million | -0.403x | -24.90% |
| 2014-03-31 | $48.28 Million | $-15.56 Million | -0.322x | -117.63% |
| 2013-03-31 | $-5.30 Million | $-9.69 Million | 1.828x | -89.28% |
| 2011-03-31 | $-6.42K | $-109.42K | 17.052x | -- |
About VivoSim Labs, Inc.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as… Read more